
    
      This is a single center, open-label, randomized, seven-treatment, seven-period, crossover
      design. The study will consist of a screening phase, a treatment phase, and a follow-up phone
      call. Approximately 24 healthy adult subjects (male or female) will be enrolled.
    
  